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Research on Children With
Hypertrophic Cardiomyopathy
The Hypertrophic Cardiomyopathy Association is a 501c3 non-
profit organization founded in 1996 to serve the hypertrophic
cardiomyopathy (HCM) community in matters of advocacy, sup-
port, and education. The Hypertrophic Cardiomyopathy Associ-
ation monitors publications on HCM daily, and after review of the
paper by Sreeram et al. (1) from Germany and the United
Kingdom regarding the use of a novel strategy of radiofrequency
ablation in HCM children with obstruction, I was left wondering
why these children were experimented on at all.
HCM patients, particularly children, have a history of being
harmed by research and unbridled enthusiasm to use novel techniques,
unfortunately at great risk to these already compromised patients. I
remain perplexed with why the authors aggressively have promoted an
invasive intervention to reduce outflow obstruction in children with an
experimental technique when suitable therapies have been used,
tested, and proven in adults and then used safely in children.
The standard of care for patients with HCM with obstruction
(American College of Cardiology [2,3] as well as American Heart
ssociation [3] and European Society of Cardiology [2] through
their consensus recommendations and guidelines [2003 and
2011]), was abandoned in this study. In the past decade, these
societies have agreed that invasive interventions to remove outflow
obstruction in HCM should be reserved for those with drug-
refractory symptoms and not as a first-line approach. Further,
these recommendations have served patients well: complication
rates have decreased and quality of life has improved. The use of
tiredness as an inclusion criterion is highly disturbing because it is
a difficult symptom to interpret in HCM patients of any age and,
when reported by a third party (parent or caregiver), highly
imprecise and is not a recognized symptom of obstruction.
The results of this study are more disturbing than the concept
alone, reporting 2 deaths and 7 serious complications, including
ventricular fibrillation, need for permanent pacing, valve replace-
ment, implantable cardioverter-defibrillator implantation, failure
and need for second attempt, burns, and myectomy—totalling a
complication rate of more than 20%.
Although the HCM community of patients appreciates the
investigation of new approaches to therapy, research on children
with HCM must be held to the highest level of ethical and
scientific standards. In our opinion, this research fell short. We
disagree with the authors. This research does not merit further
investigation in children and should be abandoned.
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Reply
We thank Dr. Maron and the Hypertrophic Cardiomyopathy
Association for their interest in our paper (1). Both take issue with
the fact that one of the symptoms in this patient cohort was
tiredness. Symptoms have to be understood in the context of being
of such severity as to interfere with the child’s daily activity and
quality of life, and parents are often the best judge of that.
The standard of care for patients with hypertrophic cardiomy-
opathy (HCM), as set out in the most recent version of the
consensus guidelines, is curiously reticent when it comes to the
care of children with symptomatic HOCM (2). It makes no
mention of radiofrequency ablation, although this has been re-
ported (3). The only reference to invasive therapy in childhood is
the surgical series by Theodoro et al. (4) from the Mayo Clinic. In
this small series (n 25), 20% of patients had no reported symptoms.
Does this imply that surgery in these children was experimental or
unnecessary? The overall complication rate was similar to that re-
ported in our study (intra-aortic balloon pump, n 2; early AICD or
pacemaker implantation, n 3; and pericardiectomy, n 1). Should
we accept this uncritically as the gold standard?
There are few studies reporting on the efficacy of pharmacologic
therapy for symptomatic children with HOCM. Reasonable ques-
tions that may be asked are: which drug(s) and at what level of
evidence? It would be quite wrong to state as established fact that
suitable therapies have been “used, tested, and proven in adults and
then used safely in children,” when this is clearly not the case.
Symptomatic children with severe obstruction may represent
the worst end of the spectrum of HCM. One may argue that adult
patients have selected themselves out as having a better prognosis
simply by having lived longer. The absence of an alternative to
open heart surgery undoubtedly has resulted in a conservative
approach to HOCM in childhood. Maintaining the status quo is
not of benefit for symptomatic children with an incurable and
progressive disease. Most parent groups support efforts by the medical
profession to improve the quality of life of their children. The
theoretical considerations and rationale for the use of radiofrequency
ablation are described clearly in our paper. Avoiding complications is
paramount, but any new approach has an element of a learning curve;
this was minimized by the authors’ experience in catheter ablation
techniques, but lessons learned will improve outcomes further.
Measuring ventricular septal thickness is meaningless, because
this will remain unchanged regardless of whether a patient under-
goes surgery or pharmacological therapy. What is important is
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children to reach adult life. HCM is a leading cause of sudden
death in young people worldwide (5). Restricting physical activity
in young persons is impracticable, placing the onus further on the
pediatric cardiologist to make timely management decisions.
Newer techniques that are effective, repeatable, reproducible, easier
to apply, and result in a shorter hospital stay and reduced costs
therefore deserve a fair hearing and should be welcome.
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